DK0462210T3 - Vacciner mod ikke-typebestemmelige Haemophilus influenzae - Google Patents

Vacciner mod ikke-typebestemmelige Haemophilus influenzae

Info

Publication number
DK0462210T3
DK0462210T3 DK90905112.0T DK90905112T DK0462210T3 DK 0462210 T3 DK0462210 T3 DK 0462210T3 DK 90905112 T DK90905112 T DK 90905112T DK 0462210 T3 DK0462210 T3 DK 0462210T3
Authority
DK
Denmark
Prior art keywords
determinable
vaccines
extracting
haemophilus influenzae
influenzae
Prior art date
Application number
DK90905112.0T
Other languages
Danish (da)
English (en)
Inventor
Gary W Zlotnick
Bruce A Green
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of DK0462210T3 publication Critical patent/DK0462210T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1242Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK90905112.0T 1989-03-09 1990-03-09 Vacciner mod ikke-typebestemmelige Haemophilus influenzae DK0462210T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32097189A 1989-03-09 1989-03-09

Publications (1)

Publication Number Publication Date
DK0462210T3 true DK0462210T3 (da) 1994-10-10

Family

ID=23248627

Family Applications (2)

Application Number Title Priority Date Filing Date
DK90905112.0T DK0462210T3 (da) 1989-03-09 1990-03-09 Vacciner mod ikke-typebestemmelige Haemophilus influenzae
DK94100492T DK0606921T3 (da) 1989-03-09 1990-03-09 Fremgangsmåde til isolering af Haemophilus influenzae protein E

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94100492T DK0606921T3 (da) 1989-03-09 1990-03-09 Fremgangsmåde til isolering af Haemophilus influenzae protein E

Country Status (13)

Country Link
US (4) US5601831A (es)
EP (2) EP0606921B1 (es)
JP (1) JP2955014B2 (es)
KR (1) KR100188323B1 (es)
AT (2) ATE110965T1 (es)
AU (1) AU648251B2 (es)
CA (1) CA2047681C (es)
DE (2) DE69012318T2 (es)
DK (2) DK0462210T3 (es)
ES (2) ES2150450T3 (es)
FI (1) FI914241A0 (es)
NO (1) NO913518L (es)
WO (1) WO1990010458A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340888C (en) * 1988-09-01 2000-02-01 Algis Anilionis Vaccines and diagnostic assays for haemophilus influenzae
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6797272B1 (en) 1991-10-16 2004-09-28 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
DE69423383T2 (de) * 1993-05-13 2000-08-24 American Cyanamid Co Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
US20020032316A1 (en) * 1995-03-31 2002-03-14 Cantab Pharmaceuticals Research Limited Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
AU716806B2 (en) * 1995-04-17 2000-03-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
AR003125A1 (es) * 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
GB9513074D0 (en) * 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6207157B1 (en) * 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
WO2002089839A1 (en) * 2001-05-03 2002-11-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella catarrhalis
US20040126381A1 (en) * 1996-04-23 2004-07-01 Xin-Xing Gu Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella
KR20010032000A (ko) * 1997-11-12 2001-04-16 프리돌린 클라우스너, 롤란드 비. 보레르 레티노이드 길항제를 이용한 티-보조 세포 제2형 중재면역 질환의 치료
US6255050B1 (en) * 1998-05-22 2001-07-03 Lorne Park Research, Inc. Dynamic hybridization system
DK1189935T3 (da) 1999-06-25 2009-02-09 Wyeth Corp Ekstraktion af integrale membranproteiner
US7101989B1 (en) 1999-07-09 2006-09-05 University Of North Carolina At Chapel Hill DsrA protein and polynucleotides encoding the same
US6391313B1 (en) * 1999-07-15 2002-05-21 Aventis Pasteur Limited Multi-component vaccine to protect against disease caused by Haemophilus influenzae and Moraxella catarrhalis
CA2382221A1 (en) * 1999-08-20 2001-03-01 H. Shaw Warren Outer membrane protein a, peptidoglycan-associated lipoprotein, and murein lipoprotein as therapeutic targets for treatment of sepsis
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
CA2418036A1 (en) * 2000-07-31 2002-02-07 Yale University Innate immune system-directed vaccines
US20030232055A1 (en) * 2000-07-31 2003-12-18 Ruslan Medzhitov Innate immune system-directed vaccines
GB0025486D0 (en) * 2000-10-17 2000-11-29 Smithkline Beecham Biolog Novel compounds
US20030175287A1 (en) * 2001-01-03 2003-09-18 Yale University Innate immune system-directed vaccines
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
US6834384B2 (en) * 2001-03-14 2004-12-21 General Instrument Corporation Methods and apparatus for upgrading firmware in an embedded system
WO2002098369A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
JP2004535187A (ja) 2001-06-07 2004-11-25 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
AU2002310760A1 (en) * 2001-06-12 2002-12-23 Glaxosmithkline Biologicals S.A. Proteins derived from non-typable haemophilus influenzae (nthi) strain
GB0117762D0 (en) * 2001-07-20 2001-09-12 Glaxosmithkline Biolog Sa Novel compounds
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
BR0308441A (pt) * 2002-03-15 2005-01-18 Wyeth Corp Proteìna variante de p4 de haemophilus influenzae não tipificável, composição imunogênica, molécula de nucleotìdeo isolada, célula hospedeira, e, métodos para induzir uma resposta imune em um ser humano contra h. influenzae não tipificável, e para produzir uma proteìna variante de p4
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
ME01334B (me) 2005-04-08 2013-12-20 Wyeth Llc Polivalentni pripravak konjugata pneumokoknog polisaharida s proteinom
KR20070047455A (ko) * 2005-11-02 2007-05-07 삼성에스디아이 주식회사 전자 방출 표시 디바이스
CA2638760A1 (en) 2006-03-07 2007-09-13 Vaxinnate Corporation Compositions that include hemagglutinin, methods of making and methods of use thereof
PT1915913E (pt) * 2006-10-23 2016-02-16 Nestec Sa Modulação do sabor e do aroma de produtos lácteos por biotransformação
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
KR20110111381A (ko) * 2009-01-07 2011-10-11 오츠카 세이야쿠 가부시키가이샤 전 인플루엔자균의 측정방법
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
PE20140173A1 (es) 2010-09-10 2014-02-20 Wyeth Llc Variantes no lipidadas de antigenos orf2086 de neisseria meningitidis
TW201302779A (zh) * 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
CN107249626A (zh) 2015-02-19 2017-10-13 辉瑞大药厂 脑膜炎奈瑟球菌组合物及其方法
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) * 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4220722A (en) 1978-02-10 1980-09-02 Syva Company Method for conjugating to polyamino compounds employing haloacyl groups and compositions prepared thereby
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
US4661347A (en) 1982-11-12 1987-04-28 Scripps Clinic Cytotoxic compositions
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4873090A (en) * 1985-03-27 1989-10-10 Broncostat Pty. Limited Non-adjuvenated vaccine
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
JP2534529B2 (ja) * 1986-07-24 1996-09-18 ブリティシュ・テレコミュニケ−ションズ・パブリック・リミテッド・カンパニ 放射発生器
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens

Also Published As

Publication number Publication date
KR100188323B1 (ko) 1999-06-01
US5955580A (en) 1999-09-21
DE69033600D1 (de) 2000-09-07
JPH07508972A (ja) 1995-10-05
CA2047681A1 (en) 1990-09-10
ES2063965T3 (es) 1995-01-16
AU648251B2 (en) 1994-04-21
ES2150450T3 (es) 2000-12-01
NO913518L (no) 1991-10-29
JP2955014B2 (ja) 1999-10-04
WO1990010458A1 (en) 1990-09-20
AU5332690A (en) 1990-10-09
US5780601A (en) 1998-07-14
EP0606921B1 (en) 2000-08-02
EP0462210B1 (en) 1994-09-07
US6420134B1 (en) 2002-07-16
NO913518D0 (no) 1991-09-06
DE69012318T2 (de) 1995-03-09
DE69012318D1 (de) 1994-10-13
FI914241A0 (fi) 1991-09-09
EP0606921A1 (en) 1994-07-20
ATE195076T1 (de) 2000-08-15
DK0606921T3 (da) 2000-09-04
CA2047681C (en) 2000-02-01
DE69033600T2 (de) 2001-04-05
ATE110965T1 (de) 1994-09-15
EP0462210A1 (en) 1991-12-27
US5601831A (en) 1997-02-11

Similar Documents

Publication Publication Date Title
DK0462210T3 (da) Vacciner mod ikke-typebestemmelige Haemophilus influenzae
CA2069450A1 (fr) Procede de fabrication d'un materiau pour osteoplastie a partir d'un tissu osseux naturel et materiau obtenu par ce procede
NO871333L (no) Kinolin-3-karboksylsyrederivater, fremgangsmaate til fremstilling og anvendelse derav.
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
CA2005291A1 (en) Feline infectious peritonitis virus diagnostic tools
EP0272040A3 (en) Thermodynamically-stable aqueous perfluorocarbon microemulsion useful as blood gas control or calibrator
DK694687A (da) Hidtil ukendte oligosaccharider, immunogener og vacciner og fremgangsmaader til fremstilling af disseoligosaccharider, immunogener og vacciner
PH25587A (en) Mixed crystals of insulin, insulin derivatives, a process for the preparation of these mixed crystals, pharmaceutical agents containing these mixed crystals,, theu use thereof for the treatment of diabetes mellitus
LV5765A4 (lv) (S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats
ES2001875A6 (es) Procedimiento para preparar nuevos derivados de aminoacidos
JPS5359018A (en) Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
MY103362A (en) Production of proteins in active forms
DE68915046D1 (de) Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
DK597786D0 (da) Krystallinske salte af aryloxypropanolaminer og fremgangsmaade til fremstilling heraf
ATE21484T1 (de) An menschliche fibroblastenzellen adaptierte hepatitis-a-viren.
NO870834D0 (no) Glysero-3(2)-fosfo-l-serinderivater og salter derav, fremgangsmaater for fremstilling derav og farmasoeytiske preparater inneholdende derivatene.
HU892532D0 (en) Process for producing synthetic peptones and veterinary preparatives containing these compounds
HUT41632A (en) Process for preparing agents for the enhancement of protein absorption
JPS53127808A (en) Preparation of human albumin
DE3763312D1 (de) Verfahren zur herstellung von hexaalkyldisilan.
DK44487D0 (da) 1-oe3-(2-hydroxy-3-alkylaminopropoxy)-2-thienylaa-3-phenyl-1-propanon eller syreadditionssalt deraf samt fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende en saadan forbindelse
ATE7267T1 (de) Impfstoff und verfahren zu seiner herstellung.
DK401088A (da) Cephalosporinforbindelse, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende den
JPS5559146A (en) Isolation of phenylalanine
UA25318C2 (uk) Спосіб отримання розчину гіфларину для ін'єкцій